Kavya Ramkumar

TL;DR: In this paper, the authors used tumor expression data and non-negative matrix factorization to identify four SCLC subtypes defined largely by differential expression of transcription factors ASCL1, NEUROD1, and POU2F3 or low expression of all three transcription factor signatures accompanied by an Inflamed gene signature.

TL;DR: STING pathway activation in NSCLC predicts features of immunotherapy response and is enhanced by cisplatin treatment, suggesting a possible predictive biomarker, and mechanism, for improved response to chemo-immunotherapy combinations.

TL;DR: It is shown that combined treatment of SRA737, an oral CHK1 inhibitor, and anti-PD-(L)1 leads to an anti-tumor response in multiple cancer models, including SCLC.

TL;DR: In this article, the expression and regulation of ACE2 and TMPRSS2 were investigated using a variety of normal and malignant models and tissues from the aerodigestive and respiratory tracts, and they found that ACE2 expression is restricted to a select population of epithelial cells.

TL;DR: A novel model of SARS-CoV-2 pathogenesis is suggested in which infected cells shift toward an increasingly mesenchymal state and lose ACE2 expression, along with its acute respiratory distress syndrome-protective effect, in a ZEB1-dependent manner.